Bristol Myers Squibb Falls as Analyst Downgrade Appears to Pressure Shares

Bristol Myers Squibb (BMY) is down 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is an analyst downgrade that appears to have weakened confidence in Bristol Myers Squibb’s drug pipeline and near-term risk profile. This could also be because investors are reassessing how much upcoming clinical data and future product launches can offset pressure on older blockbuster medicines.

Details:

Leerink Partners downgraded Bristol Myers Squibb to Market Perform from Outperform and lowered its price target, citing greater skepticism around key late-stage pipeline candidates.

The analyst note focused on risk around upcoming clinical readouts, suggesting there is less conviction that several important development programs will deliver strong enough results to support the prior bullish view.

Bristol Myers Squibb’s most recent quarterly update showed the company raised its 2026 revenue outlook and non-GAAP earnings outlook, so today’s decline does not appear tied to a fresh earnings warning.

The company is not scheduled to report third-quarter 2026 results until October 29, which may have left the downgrade as the market’s main near-term catalyst.

Sources:

Yahoo Finance, Bristol Myers Squibb, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BMY Insider Trading Activity

$BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

CRISTIAN MASSACESI (EVP,Chief Med Offr,Head of Dev) sold 6,249 shares for an estimated $403,497
PHIL M HOLZER (SVP and Controller) sold 500 shares for an estimated $33,750

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BMY Hedge Fund Activity

We have seen 1,134 institutional investors add shares of $BMY stock to their portfolio, and 1,128 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 71,713,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,132,128,528
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 67,595,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,894,834,098
PRICE T ROWE ASSOCIATES INC /MD/ added 21,457,405 shares (+209.3%) to their portfolio in Q2 2026, for an estimated $1,236,375,676
BLACKROCK, INC. added 8,702,106 shares (+5.1%) to their portfolio in Q2 2026, for an estimated $501,415,347
PACER ADVISORS, INC. added 7,995,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $460,712,867
CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 6,479,804 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $373,366,306
NORDEA INVESTMENT MANAGEMENT AB added 6,019,226 shares (+296.1%) to their portfolio in Q2 2026, for an estimated $346,827,802

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BMY Government Contracts

We have seen $12,144,519 of award payments to $BMY over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS: $848,445
ABECMA FOR CAR-T: $378,650

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

REPRESENTATIVE MIKE KELLY sold up to $50,000 on 05/07.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 2 analysts offer price targets for $BMY in the last 6 months, with a median target of $60.5.

Here are some recent targets:

Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 07/06/2026
Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.